Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Pharvaris N.V. (NASDAQ:PHVS) have earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $51.0769.

PHVS has been the topic of a number of analyst reports. Morgan Stanley upped their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. UBS Group set a $74.00 price objective on Pharvaris in a research report on Wednesday, May 13th. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Thursday. Citizens Jmp lifted their target price on Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research note on Friday.

Insider Activity at Pharvaris

In related news, CEO Berndt Modig sold 2,291 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $31.07, for a total transaction of $71,181.37. Following the completion of the transaction, the chief executive officer owned 135,209 shares in the company, valued at $4,200,943.63. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the sale, the director owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 158,322 shares of company stock valued at $5,371,886 over the last 90 days. Company insiders own 11.84% of the company’s stock.

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Wellington Management Group LLP purchased a new position in shares of Pharvaris during the third quarter worth about $43,282,000. 5AM Venture Management LLC purchased a new position in Pharvaris in the second quarter valued at about $27,581,008,000. Paradigm Biocapital Advisors LP raised its stake in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after buying an additional 772,583 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Pharvaris in the second quarter worth $26,677,000. Finally, Balyasny Asset Management L.P. purchased a new stake in Pharvaris in the 3rd quarter worth approximately $15,613,000.

Pharvaris Stock Up 3.2%

PHVS opened at $35.14 on Monday. The firm has a 50 day moving average price of $33.71 and a 200-day moving average price of $30.09. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -11.52 and a beta of -2.31. Pharvaris has a twelve month low of $20.65 and a twelve month high of $36.93.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, analysts expect that Pharvaris will post -2.97 earnings per share for the current year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.